MedTrace Logo

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

NCT05611229 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1975

Last updated 2023-04-06

No results posted yet for this study

Summary

This was an observational study utilizing electronic health record (EHR)-derived data collected retrospectively during routine care of real-world patients with advanced melanoma from NOBLE (Novartis Braf+ meLanoma patients ObsErvational) dataset.

Conditions

Interventions

DRUG

Nivolumab

Nivolumab

DRUG

Pembrolizumab

Pembrolizumab

COMBINATION_PRODUCT

Dabrafenib+Trametinib

Dabrafenib+Trametinib

COMBINATION_PRODUCT

Ipilimumab+Nivolumab

Ipilimumab+Nivolumab

COMBINATION_PRODUCT

Vemurafenib+Cobimetinib

Vemurafenib+Cobimetinib

COMBINATION_PRODUCT

Encorafenib+Binimetinib

Encorafenib+Binimetinib

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-16
Primary Completion
2021-12-03
Completion
2021-12-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05611229 on ClinicalTrials.gov